Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
1. Tvardi completed its merger with Cara Therapeutics in April. 2. The company’s lead drug, TTI-101, is in Phase 2 for IPF. 3. Piper Sandler initiated coverage, rating TVRD as overweight with $78 target. 4. TVRD is well-funded, expected to last into the second half of 2026. 5. TTI-109, a next-gen drug, is also under development for STAT3.